Sustol granisetron extended release regulatory update

Heron said FDA now expects to complete its review of an NDA from Heron for Sustol granisetron for chemotherapy-induced nausea and vomiting (CINV) in late February. The PDUFA date was Jan. 17. Sustol is under review to prevent acute and delayed CINV associated with moderately or highly emetogenic chemotherapy regimens. ...